|
|
Blood, 1 December 2004, Vol. 104, No. 12, pp. 3697-3704.
Prepublished online as a Blood First Edition Paper on August 3, 2004; DOI 10.1182/blood-2003-12-4114.
 Previous Article | Table of Contents | Next Article 
NEOPLASIA
Overexpression of the NOTCH ligand JAG2 in malignant plasma cells from multiple myeloma patients and cell lines
Christiane Houde,
Yulin Li,
Lynda Song,
Kevin Barton,
Qing Zhang,
John Godwin,
Sucha Nand,
Amir Toor,
Serhan Alkan,
N. Veronique Smadja,
Hervé Avet-Loiseau,
Carmen S. Lima,
Lucio Miele, and
Lionel J. Coignet
From the Department of Pathology and Department of Medicine, Loyola University Medical Center, Cardinal Bernardin Cancer Center, Maywood, IL; Department of Cancer Genetics, Roswell Park Cancer Institute, Buffalo, NY; Cytogenetic Laboratory, Hopital St-Antoine, Paris, France; Laboratoire d'Hématologie, Institut de Biologie, Nantes, France; and Hematology and Hemotherapy Center, State University of Campinas, Cidade Universitária "Zeferino Vaz," São Paulo, Brazil.
The NOTCH ligand, JAG2, was found to be overexpressed in malignant plasma cells from multiple myeloma (MM) patients and cell lines but not in nonmalignant plasma cells from tonsils, bone marrow from healthy individuals, or patients with other malignancies. In addition, JAG2 overexpression was detected in 5 of 5 patients with monoclonal gammopathy of undetermined significance (MGUS), an early phase of myeloma disease progression. This overexpression appears to be a consequence of hypomethylation of the JAG2 promoter in malignant plasma cells. An in vitro coculture assay was used to demonstrate that JAG2 induced the secretion of interleukin-6 (IL-6), vascular endothelial growth factor (VEGF), and insulin-like growth factor-1 (IGF-1) in stromal cells. Further, the induction of IL-6 secretion was blocked in vitro by interference with anti–Notch-1 monoclonal antibodies raised against the binding sequence of Notch-1 with JAG2. Taken together, these results indicate that JAG2 overexpression may be an early event in the pathogenesis of multiple myeloma involving IL-6 production.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
P. Ghoshal, A. J. Nganga, J. Moran-Giuati, A. Szafranek, T. R. Johnson, A. J. Bigelow, C. M. Houde, H. Avet-Loiseau, D. J. Smiraglia, N. Ersing, et al.
Loss of the SMRT/NCoR2 Corepressor Correlates with JAG2 Overexpression in Multiple Myeloma
Cancer Res.,
May 15, 2009;
69(10):
4380 - 4387.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. C. Sprynski, D. Hose, L. Caillot, T. Reme, J. D. Shaughnessy Jr, B. Barlogie, A. Seckinger, J. Moreaux, M. Hundemer, M. Jourdan, et al.
The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor
Blood,
May 7, 2009;
113(19):
4614 - 4626.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Rosati, R. Sabatini, G. Rampino, A. Tabilio, M. Di Ianni, K. Fettucciari, A. Bartoli, S. Coaccioli, I. Screpanti, and P. Marconi
Constitutively activated Notch signaling is involved in survival and apoptosis resistance of B-CLL cells
Blood,
January 22, 2009;
113(4):
856 - 865.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. A. Huff and W. Matsui
Multiple Myeloma Cancer Stem Cells
J. Clin. Oncol.,
June 10, 2008;
26(17):
2895 - 2900.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Nefedova, D. M. Sullivan, S. C. Bolick, W. S. Dalton, and D. I. Gabrilovich
Inhibition of Notch signaling induces apoptosis of myeloma cells and enhances sensitivity to chemotherapy
Blood,
February 15, 2008;
111(4):
2220 - 2229.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. G. Leong and A. Karsan
Recent insights into the role of Notch signaling in tumorigenesis
Blood,
March 15, 2006;
107(6):
2223 - 2233.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Miele
Notch Signaling
Clin. Cancer Res.,
February 15, 2006;
12(4):
1074 - 1079.
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Quesnel
Multiple myeloma: all roads lead to cyclin D
Blood,
July 1, 2005;
106(1):
1 - 2.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. A. Jungbluth, S. Ely, M. DiLiberto, R. Niesvizky, B. Williamson, D. Frosina, Y.-T. Chen, N. Bhardwaj, S. Chen-Kiang, L. J. Old, et al.
The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation
Blood,
July 1, 2005;
106(1):
167 - 174.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Takeuchi, Y. Adachi, and Y. Ohtsuki
Skeletrophin, a Novel Ubiquitin Ligase to the Intracellular Region of Jagged-2, Is Aberrantly Expressed in Multiple Myeloma
Am. J. Pathol.,
June 1, 2005;
166(6):
1817 - 1826.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Matsumoto and M. Abe
The Importance of Notch Signaling in Myeloma Cell-Osteoclast Interactions
IBMS BoneKEy,
February 1, 2005;
2(2):
7 - 10.
[Full Text]
[PDF]
|
|
|
|
|
